The Sickle Cell Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sickle Cell Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued products.
GlobalData tracks 135 drugs in development for Sickle Cell Disease by 102 companies/universities/institutes. The top development phase for Sickle Cell Disease is preclinical with 62 drugs in that stage. The Sickle Cell Disease pipeline has 120 drugs in development by companies and 15 by universities/ institutes. Some of the companies in the Sickle Cell Disease pipeline products market are: Pfizer, Novartis and Centre for Stem Cell Research.
The key targets in the Sickle Cell Disease pipeline products market include Hemoglobin Subunit Beta (Beta Globin or Hemoglobin Beta Chain or HBB), B Cell Lymphoma/Leukemia 11A (B Cell CLL/Lymphoma 11A or COUP TF Interacting Protein 1 or Ecotropic Viral Integration Site 9 Protein Homolog or Zinc Finger Protein 856 or BCL11A), and Hemoglobin Subunit Gamma 1 (Gamma Globin or Gamma1 Globin or Hb F Agamma or Hemoglobin Gamma 1 Chain or Hemoglobin Gamma A Chain or HBG1).
The key mechanisms of action in the Sickle Cell Disease pipeline product include Hemoglobin Subunit Beta (Beta Globin or Hemoglobin Beta Chain or HBB) Activator with ten drugs in Pre-Registration. The Sickle Cell Disease pipeline products include nine routes of administration with the top ROA being Oral and 15 key molecule types in the Sickle Cell Disease pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Sickle Cell Disease overview
Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.
For a complete picture of Sickle Cell Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
